(MT Newswires) -- Novo Nordisk A/S (NVO) will sell its Wegovy obesity drug in larger European markets in 2023 after resolving production problems that has held back sales of the weekly injection in the US. Chief Executive Officer Lars Fruergaard Jorgensen speaks on "Bloomberg Markets."
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
905.5 DKK | -0.81% | -0.54% | +29.64% |
05-16 | Health Care Flat as Momentum Wanes -- Health Care Roundup | DJ |
05-16 | Novo Nordisk Reports Fire Incident at Under-Construction Facility in Kalundborg, Denmark | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.64% | 593B | |
+32.36% | 694B | |
-1.60% | 371B | |
+20.07% | 331B | |
+6.04% | 290B | |
+14.64% | 239B | |
+10.18% | 209B | |
-3.23% | 209B | |
+9.27% | 169B | |
+0.45% | 164B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk Sees Strong Demand for Obesity Drug